O
RTHOTOPIC LIVER transplantation has become an accepted treatment for end-stage chronic liver disease, with patient survival rates of 80% to 90%. 1 In addition, it can be a life-saving procedure in patients with fulminant hepatic failure and an effective treatment for several metabolic disorders. Currently, a total of about 10,000 liver transplantations are performed each year in the United States and Europe.
The first human liver transplantation was performed by Starzl in 1963. 2 During the 2 decades that followed, liver transplantation was usually a long and risky operation with large amounts of blood loss. 3, 4 Bleeding was the main cause of mortality in those days. During the past 15 years, a combination of improvements in surgical technique, anesthesiology care, and organ preservation has contributed to a marked decrease in perioperative transfusion requirements and decreased patient morbidity and mortality rates. In addition, research on perioperative changes in coagulation and fibrinolysis has improved the understanding of the hemostatic disorders that are associated with liver transplantation, and this has enabled clinicians to develop strategies to correct the specific hemostatic abnormalities. [5] [6] [7] Although blood transfusion requirements have steadily decreased during the last decades in most liver transplant centers, a significant negative correlation between blood loss and posttransplantation outcome can still be found. [8] [9] [10] In the early 90s, Mor et al, 9 from the group in Dallas, were among the first to report on the negative association between intraoperative blood transfusion requirement and postoperative outcome variables, such as graft and patient survival, length of stay in the intensive care unit, and infectious complications. In a more recent report from the group in Berlin, Germany, it was also noted that patients receiving more than 9 to 10 units of red blood cells intraoperatively have a higher postoperative infection rate and morbidity and decreased patient survival. 10 In the Groningen series of adult patients undergoing liver transplantation, significantly lower survival rates were observed when intraoperative red blood cell transfusion requirements increased (Fig 1) . Similar observations have been made in the pediatric population. 11 In a multivariate analysis, blood transfusion was identified as an independent risk factor for actual survival after pediatric liver transplantation. 11 Using uni-and multivariate analyses of a large series of patients, specific surgical and nonsurgical risk factors for transfusion requirements in patients undergoing liver transplantation have been identified. 8,12 Independent risk factors for perioperative blood transfusions are preoperative medical condition (Child-Pugh classification, United Network of Organ Sharing classification), kidney function, year of transplantation, cold ischemia time of the donor liver, and variables related to the surgical technique such as the operative time. 8, 12, 13 Besides the obvious relation between surgical skills and experience on one side and perioperative blood loss on the other side, specific intraoperative hemostatic disorders, especially hyperfibrinolysis, have been shown to play an important role in the origin of nonsurgical blood loss during liver transplantation. 5, 6, 14 In the normal situation, hemostatic function is maintained by a delicate balance between 2 proteolytic cascades: the coagulation system and the fibrinolytic system. The coagulation system becomes immediately activated when hemostasis is necessary to prevent bleeding from an injured vessel, whereas fibrinolysis is a more slow-acting mechanism, responsible for removal of fibrin clots once the integrity of the vessel wall has been restored (Fig 2) .
The liver plays an important role in the production and regulation of proteins of the coagulation and fibrinolysis cascades. Abnormal activation of the fibrinolytic system has long been recognized as one of the changes in the hemostatic system during liver transplantation. 5, 6 It has been shown that increased plasma levels of tissue-plasminogen activator (t-PA), the most important endogenous activator of plasminogen, are responsible for the hyperfibrinolysis frequently observed during liver transplantation. 15 Especially during the anhepatic and early postreperfusion periods, t-PA plasma levels increase rapidly. Lack of hepatic clearance during the anhepatic period and release of t-PA from the ischemically injured endothelium of the donor liver on reperfusion are believed to be responsible for this. When there is immediate good function of the donor liver, plasma levels of t-PA usually decline during the last stage of the operation and levels are usually back to normal values at the end of the procedure. 15 However, t-PA has a very high affinity for fibrin, and activation of the fibrinolytic system at the site of hemostatic clots at the surgical wounds will have started before this and may continue throughout the whole procedure. Elevated t-PA levels result in a consumption of its naturally occurring inhibitor, plasminogen activator inhibitor-1, and subsequent low plasminogen activator inhibitor-1 activity. 15 The t-PA increase observed during liver transplantation leads to the conversion of plasminogen into plasmin. Plasmin degrades fibrin, leading to the premature breakdown of hemostatic clots and subsequent increased blood loss and transfusion requirements. Identification of hyperfibrinolysis as one of the underlying mechanisms of increased blood loss during liver transplantation has provided support for a more goal-directed therapy, using antifibrinolytic drugs. Antifibrinolytic drugs are available as direct inhibitors of plasminogen (lysine analogs) or as inhibitors of plasmin (serine protease inhibitors). There is a large amount of clinical experience with these drugs, especially in cardiac surgery.
APROTININ AS AN ANTIFIBRINOLYTIC DRUG
Aprotinin is a serine protease inhibitor and a potent antifibrinolytic agent. This naturally occurring polypeptide was first described by Kraut et al 16 in 1930. It is derived from bovine
